Literature DB >> 21479347

Do standardised prognostic algorithms reflect local practice? Application of EORTC risk tables for non-muscle invasive (pTa/pT1) bladder cancer recurrence and progression in a local cohort.

Rajiv Pillai1, Duolao Wang, Erik K Mayer, Paul Abel.   

Abstract

A risk calculator algorithm to allow prediction of probabilities of 1- and 5-year recurrence and progression rates in individuals with pTa/pT1 bladder cancer has been proposed by the European Organisation for Research and Treatment of Cancer (EORTC) and was incorporated into the European Association of Urology guidelines in 2006. We attempted to validate this algorithm in a cohort of patients with known outcome. Prognostic data were collected from a consecutively presenting cohort of 109 patients with non-muscle invasive (pTa/pT1) transitional cell cancer (TCC) at a single institution between 1983 and 1985. Using the same statistical models as in the EORTC original paper, predicted probabilities of 1- and 5-year recurrence and progression were calculated. Patients were divided into four risk groups for recurrence (Ir-IVr) and progression (Ip-IVp), respectively, using six prognostic criteria. These were then compared to the probabilities predicted in the EORTC algorithm. The predicted 1- and 5-year probabilities of recurrence were significantly higher in the study population as compared to the original EORTC algorithm for all four risk groups. The predicted 1-year probabilities for progression in groups Ip/IIIp and at 5-years for groups Ip/IIp were in accordance with the original algorithm, but were higher for the other progression groups. The concordance for the model of prediction using the study group for recurrence at 1 and 5 years was 62 and 63%, respectively, and for progression was 65 and 67%, respectively. We were unable to validate the proposed algorithm in our group of patients. Although our study has limitations that prevent firm conclusions on the validity of the algorithm, it does expose some of the drawbacks of standardised nomograms when applied to local clinical practice.

Entities:  

Mesh:

Year:  2011        PMID: 21479347      PMCID: PMC5720000          DOI: 10.1100/tsw.2011.77

Source DB:  PubMed          Journal:  ScientificWorldJournal        ISSN: 1537-744X


  8 in total

1.  Selection of adjuvant intravesical therapies using the European Organization for Research and Treatment of Cancer scoring system in patients at intermediate risk of non-muscle-invasive bladder cancer.

Authors:  Mitsuo Ofude; Yasuhide Kitagawa; Hiroshi Yaegashi; Kouji Izumi; Satoru Ueno; Yoshifumi Kadono; Hiroyuki Konaka; Atsushi Mizokami; Mikio Namiki
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-10       Impact factor: 4.553

2.  Applicability of the EORTC risk tables to predict outcomes in non-muscle-invasive bladder cancer in Turkish patients.

Authors:  Muhammet Fatih Kılınç; Göksel Bayar; Ayhan Dalkılıç; Nurettin Cem Sönmez; Serdar Arısan; Soner Güney
Journal:  Turk J Urol       Date:  2017-01-06

3.  Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG's receptor ILT2 on peripheral CD8+ T cells.

Authors:  Francois Desgrandchamps; Joel LeMaoult; Annabelle Goujon; Adrien Riviere; Antonio Rivero-Juarez; Malika Djouadou; Amory de Gouvello; Clement Dumont; Ching-Lien Wu; Stephane Culine; Jerome Verine; Nathalie Rouas-Freiss; Christophe Hennequin; Alexandra Masson-Lecomte; Edgardo D Carosella
Journal:  Oncotarget       Date:  2018-09-04

4.  EORTC risk tables - their usefulness in the assessment of recurrence and progression risk in non-muscle-invasive bladder cancer in Polish patients.

Authors:  Edyta M Borkowska; Adam Jędrzejczyk; Piotr Marks; James W F Catto; Bogdan Kałużewski
Journal:  Cent European J Urol       Date:  2013-04-26

5.  Who needs numbers more: patients or doctors?

Authors:  Marcin Słojewski
Journal:  Cent European J Urol       Date:  2013

6.  External validation of EORTC risk scores to predict recurrence after transurethral resection of brazilian patients with non -muscle invasive bladder cancer stages Ta and T1.

Authors:  Gilberto L Almeida; Wilson F S Busato; Carmen Marcondes Ribas; Jurandir Marcondes Ribas; Ottavio De Cobelli
Journal:  Int Braz J Urol       Date:  2016 Sep-Oct       Impact factor: 1.541

7.  Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-muscle Invasive Bladder Cancer in Asia.

Authors:  Takeshi Ieda; Satoru Muto; Fumitaka Shimizu; Masataka Taguri; Shigeto Yanada; Kousuke Kitamura; Kazutaka Terai; Keisuke Saito; Tatsuya Ogishima; Masayoshi Nagata; Hisamitsu Ide; Takatsugu Okegawa; Yoshiaki Wakumoto; Yoshiro Sakamoto; Akira Tsujimura; Raizo Yamaguchi; Kikuo Nutahara; Shigeo Horie
Journal:  EBioMedicine       Date:  2016-09-02       Impact factor: 8.143

8.  Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): A cohort analysis.

Authors:  Mateusz Jobczyk; Konrad Stawiski; Wojciech Fendler; Waldemar Różański
Journal:  Cancer Med       Date:  2020-03-26       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.